Minimum information about tolerogenic antigen-presenting cells (mitap): a first step towards reproducibility and standardisation of cellular therapies
View/ Open
Full Text
Date
2016-08-30Author
Lord, Phillip
Spiering, Rachel
Aguillon, Juan C.
Anderson, Amy E.
Appel, Silke
Benitez-Ribas, Daniel
ten Brinke, Anja
Broere, Femke
Cools, Nathalie
Cuturi, Maria Cristina
Diboll, Julie
Geissler, Edward K.
Giannoukakis, Nick
Gregori, Silvia
van Ham, S. Marieke
Lattimer, Staci
Marshall, Lindsay
Harry, Rachel A.
Hutchinson, James A.
Isaacs, John D.
Joosten, Irma
van Kooten, Cees
Lopez Diaz de Cerio, Ascension
Nikolic, Tatjana
Oral, Haluk Barbaros
Sofronic-Milosavljevic, Ljiljana
Ritter, Thomas
Riquelme, Paloma
Thomson, Angus W.
Trucco, Massimo
Vives-Pi, Marta
Martinez-Caceres, Eva M.
Hilkens, Catharien M.U.
Metadata
Show full item recordUsage
This item's downloads: 0 (view details)
Cited 36 times in Scopus (view citations)
Recommended Citation
Lord, Phillip; Spiering, Rachel; Aguillon, Juan C. Anderson, Amy E.; Appel, Silke; Benitez-Ribas, Daniel; ten Brinke, Anja; Broere, Femke; Cools, Nathalie; Cuturi, Maria Cristina; Diboll, Julie; Geissler, Edward K.; Giannoukakis, Nick; Gregori, Silvia; van Ham, S. Marieke; Lattimer, Staci; Marshall, Lindsay; Harry, Rachel A.; Hutchinson, James A.; Isaacs, John D.; Joosten, Irma; van Kooten, Cees; Lopez Diaz de Cerio, Ascension; Nikolic, Tatjana; Oral, Haluk Barbaros; Sofronic-Milosavljevic, Ljiljana; Ritter, Thomas; Riquelme, Paloma; Thomson, Angus W.; Trucco, Massimo; Vives-Pi, Marta; Martinez-Caceres, Eva M.; Hilkens, Catharien M.U. (2016). Minimum information about tolerogenic antigen-presenting cells (mitap): a first step towards reproducibility and standardisation of cellular therapies. PeerJ 4 ,
Published Version
Abstract
Cellular therapies, with tolerogenic antigen-presenting cells (tolAPC) show great promise for the treatment of autoimmune diseases and for the prevention of destructive immune responses after transplantation The methodologies for generating tolAPC vary greatly between different laboratories, making it difficult to compare data from different studies; thus constituting a major hurdle for the development of standardised tolAPC therapeutic products. Here we describe an initiative by members of the tolAPC field to generate a minimum information model for tolAPC (MITAP), providing a reporting framework that will make differences and similarities between tolAPC products transparent. In this way, MITAP constitutes a first but important step towards the production of standardised and reproducible tolAPC for clinical application.